Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Q1 2022/23 Earnings Presentation
96 slides from Coloplast A/s Class B's earnings presentation, February 2023
Slide 1: Roadshow presentation Q1 2022/23
Roadshow presentation Q1 2022/23 Making life easier STRIVE25: SUSTAINABLE GROWTH LEADERSHIP
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Solid Q1 with 7% organic growth and 29% EBIT margin
Solid Q1 with 7% organic growth and 29% EBIT margin1. Unchanged FY 2022/23 guidance of 7-8% organic growth and 28-30% EBIT margin1 REVENUE GROWTH Q1 2022/23 highlights Reported revenue (mDKK) • Organic growth of 7% and reported growth in DKK of 18%. Organic growth • Solid start in Chronic Care with
Slide 4: Q1 organic growth driven by solid start in Chronic Care
Q1 2022/23 organic growth was driven by a solid start in Chronic Care with broad based growth across regions excluding China Q1 2022/23 revenue by business area Q1 2022/23 revenue by geography Business Reported revenue FY Organic growth Share of organic Geographic Reported revenue FY Organic growth
Slide 5: Ostomy Care strong start with 8% growth in Q1
Ostomy Care is off to a strong start with 8% growth in Q1 and solid contribution from all regions excluding China Ostomy Care performance Q1 2022/23 highlights • All regions contributed to growth ex. China 13 • Solid growth contribution from Europe, driven primarily by the UK • Solid momentum in the
Slide 6: Continence Care grew 7% in Q1
Continence Care grew 7% in Q1. Continued headwind from backorders in Collecting Devices, offset by strong growth in Intermittent Catheters Continence Care performance Q1 2022/23 highlights • Growth was driven by continued solid momentum in Europe, especially the UK, and the US 11 • Sales growth in t
Slide 7: Voice & Respiratory Care contributed 9%-points to reported growth
Voice & Respiratory Care contributed 9%-points to reported growth in Q1, with a high single-digit organic growth Voice & Respiratory Care performance Q1 2022/23 highlights • The Atos Medical acquisition was completed on 31 January 2022, adding a new chronic care segment, Voice & Respiratory Care. Th
Slide 8: Wound & Skin Care grew 1% in Q1
Wound & Skin Care grew 1% in Q1. Wound Care declined 4%, impacted by a high baseline, continued backorders and COVID-19 in China Wound & Skin Care performance Q1 2022/23 highlights • Wound Care in isolation declined 4% driven by a high baseline in Q1 last 17 year, continued backorders impact, and ne
Slide 9: Strong start in Interventional Urology with 11% growth
Strong start to the year in Interventional Urology with broad-based growth of 11%, led by the Men’s Health business in the US Interventional Urology performance Q1 2022/23 highlights • Growth in the quarter was nicely balanced across business areas and geographies 23 19 18 • Men’s Health was the lar
Slide 10: Q1 reported growth up 18%, above organic growth
Q1 reported growth was up 18%, ~11%-points above organic growth, due to the inclusion of Atos Medical and currency appreciation Q1 2022/23 Revenue development (DKKm) Q1 2022/23 highlights • Organic growth was 7% or DKK 353 million, driven by: 936m DKK • Solid start in Chronic Care across geographies
Slide 11: Reported EBIT margin of 29% in Q1
Reported EBIT margin of 29%1 in Q1, reflecting an impact from cost inflation, increased level of commercial activity and amortisation costs Q1 2022/23 EBIT margin development before special items (%) Q1 2022/23 highlights • Gross margin was 68%, on par with last year • Positive impact from: price in
Slide 12: Adj. FCF in Q1 was DKK 576 million
Adj. FCF in Q1 was DKK 576 million, negatively impacted by an increase in net working capital. NWC-to-sales still expected at 24% for the FY FCF development1 FCF development Comments Q1 2022/23 highlights • Free cash flow for Q1 2022/23 was an inflow of DKK 212 million compared to an inflow of DKK 9
Slide 13: FY 2022/23 guidance: 7-8% organic growth, EBIT margin 28-30%
FY 2022/23 guidance: Organic growth of 7-8% and reported EBIT margin of 28-30%1 - reported growth adjusted to 9-10% GUIDANCE 2022/23 GUIDANCE (DKK)* KEY ASSUMPTIONS • Limited impact from COVID-19 on hospital activity across markets, except for China • Chronic Care excl. China expected to grow largel
Slide 14: FY 2022/23 guidance breakdown: input cost impact on EBIT margin
FY 2022/23 guidance breakdown: significant negative impact from input cost increases on EBIT margin Development since issue of FY guidance Revenue growth assumptions Key impacts on gross- and EBIT margin development in 2022/23 Positive Unchanged Negative 68.8 ILLUSTRATIVE Unchanged FY 2022/23 organi
Slide 15: Making it easier to be yourself
Making it easier to be yourself Leading intimate healthcare Introduction to Coloplast Stina | OC user
Slide 16: Coloplast has five business areas with global sales presence
Coloplast has five business areas all with global sales presence Group revenue 2021/22 by segment1 Group revenue 2021/22 by geography 1 Continence Care 34% European 1 markets 57% Ostomy Care Other developed 38% markets DKK DKK 26% 22.6bn 22.6bn 1 Voice & Respiratory 4 Care Interventional 5% Urology
Slide 17: Coloplast specializes in intimate healthcare needs
Coloplast specializes in intimate healthcare needs Who are our typical users How do we help them? Ostomy Care People who have had their intestine redirected to SenSura® Mio an opening in the abdominal wall Ostomy bag Continence Care People in need of bladder or bowel management SpeediCath® Flex Flex
Slide 18: The Chronic Care model secures predictable revenue stream
The Chronic Care model secures a predictable revenue stream and stable revenue growth The chronic care user flow Chronic Care condition New user Installed base of users Stable flow of loyal users Solid reimbursement Coloplast group revenues Revenue (DKK bn) Organic growth (%) 10 10 9 8 8 8 8 6 7 7 7
Slide 19: Intimate healthcare is characterized by stable industry trends
Intimate healthcare is characterized by stable industry trends 01. 01. Demographics Surgical and medical trends Growing elderly population Earlier detection and cure, increases customer base for eventually reduces addressable Coloplast products market for Coloplast treatment Limiters Drivers product
Slide 20: Strong market positions in Europe and potential outside Europe
Coloplast has strong market positions in Europe and great commercial potential outside Europe Europe Other developed Ostomy Continence Voice & Respiratory Interventional Wound Emerging Care Care Care (Laryngectomy) Urology Care Addressable market 20-21bn 15-16bn 1–1.5bn 13-14bn 24-26bn Size in DKK 4
Slide 21: Building the consumer healthcare company of the future
We are building the consumer healthcare company of the future Macro Trends Impact Commercial model Ageing population Superior, clinically differentiated products Healthcare consumerism Digital transformation Consumer preference Data and Clinical digital tools preference Price pressure Channel consol
Slide 22: Our Strive25 strategy will drive long-term value creation
Our Strive25 strategy will drive continued long-term value Continence creation through Care Ostomy Wound and revenue and earnings Care Skin Care growth Interventional Voice and Urology Respiratory Care Innovation Leadership, culture 7-9% more than 30% and organization organic growth EBIT margin1 p.a
Slide 23: Strive25 emphasis on environmental performance
With Strive25 we put emphasis on improving our environmental performance, while continuing our ongoing commitments Our mission Making life easier for people with intimate healthcare needs Our 2025 priority Our 2025 priority Improving products Reducing emissions1 and Packaging1 90% of packaging recyc
Slide 24: Incremental investments of up to 2% of revenue
We will continue to support organic growth through yearly incremental investments of up to 2% of revenue in the Strive25 period Key Investment Decision Drivers Key Investment Areas We expect to invest up to 2% Economics & Government Innovation of revenue in incremental OPEX investments Chronic Care
Slide 25: Actively pursue M&A opportunities for long-term growth
We will actively pursue M&A opportunities as a lever for long-term growth Opportunity Systematic based screening Large plays Channel expansion Portfolio expansion Early-stage & adjacencies technologies Examples: Atos Medical Hope Medical Supply1 TFL Drive Nine Continents Rocky Mountain Medical Suppl
Slide 26: Key enablers supporting the commercial model in Chronic Care
We have built key enablers to support the commercial model in our Chronic Care businesses Commercial model Key enablers Superior, clinically Direct Businesses differentiated products Coloplast Consumer Care Consumer preference Data and digital tools Clinical preference Direct to Consumer Data & Digi
Slide 27: Direct business in Chronic Care drives growth
Direct business in Chronic Care serving consumers drives improved outcomes and is a vital component of our growth Direct presence in top 5 markets and strategic rationale Coloplast Consumer presence (incl. patient support programme, Coloplast® Care) Control and continuity 1 of product supply ~30% MS
Slide 28: Clinical Performance Programme to tackle users' biggest issues
We have initiated a very ambitious Clinical Performance Programme to tackle the biggest issues users face 45 of users describe UTIs are their %* 2.7 UTIs per user on average every year1 93 % worry about leakage2 greatest challenge in life1 1 Source: Coloplast IC user survey, January 2016 (n=2,942),
Slide 29: Solid progress on Heylo and Luja
Solid progress on Heylo™ and Luja™; Luja is launching in key markets over the next 12 months Status February 2023 Expected launch Product launch initiation in February in Denmark and Finland Luja™ Product launch expected new catheter in key markets over the First pivotal study has been finalized, se
Slide 30: Leakage remains the biggest challenge for our users
Leakage remains the biggest challenge for our users 91% of people with a stoma worry about leakage1 40 % of users experience leakage onto their clothes every month2 Heylo addresses the mental burden caused by fear of leakage Control and peace of mind 1. Claessenes et. al. Gastrointestinal Nursing 20
Slide 31: Data on Heylo is promising
Data on Heylo™ is promising. Pre-pilot study shows high product performance and user preference Product performance & user experience1 Quality of life and future use1 reduction in worry of leakage 92%* % +9 emotional impact of leakage significant improvement to less leakage episodes 85 %** % 96 secu
Slide 32: Clinical program supports launches and reimbursement
The clinical program supports national launches, reimbursement applications and generates user insights Single-arm confirmatory study, n=100 Show benefit to support Drug Tariff application: • Leakage onto clothes • Quality of Life • Healthcare utilisation • Support reimbursement in DE & UK Cross-ove
Slide 33: Preventing UTIs remains one of the biggest unmet needs
Preventing UTIs % remains one of the 45% 48 biggest unmet of users consider of users are UTIs to be their worried whether needs we need to greatest challenge1 they have emptied solve for in IC their bladder4 IC users have 2-3 UTIs on average per year…2 …over a lifetime users will have up to 1 IC Val
Slide 34: Luja with Micro-hole Zone Technology addresses UTI risk factors
Luja™, our new catheter platform with Micro-hole Zone Technology™ addresses the key UTI risk factors UTI Risk Factor Model1 UTI risk factors addressed by Luja™ Intermittent General patient catheterisation conditions UTI risk factor: UTI risk factor: Non-hygienic technique Urethral trauma UTI risk fa
Slide 35: Comprehensive clinical program behind Luja
Comprehensive clinical program behind Luja™ to demonstrate the clinical relevance and difference Pivotal studies 2 multinational pivotal studies2 involving 110+ users demonstrating the impact on the key risk factors of UTI. Pilot studies Multicenter, randomised cross 8 studies comparing Luja over tr
Slide 36: Profitability supported by scalability and efficiency gains
Profitability supported by scalability and efficiency gains enabling additional innovation and commercial investments Gross Profit development, %* Cost item Development, in % of revenue* 1.5%-points 29.0 28.7 28.2 30.1 30.5 28-30 Distribution 0.2%-points 67.7 68.0 68.5 68.8 67.9 ~68 0.7%-points 4.5
Slide 37: Automation, procurement and scale in Global Operations
Automation, procurement and scale are key to bringing Global Operations to the next level 1. Automation to mitigate growth in blue-collar FTE 9% ~600 >1,000 DKK ~450m # of FTE release ~500 CAPEX investment over ~200 through automation four years (19/20 – 22/23) Salary1 (Direct labour) 19/20 20/21 21
Slide 38: Global Business Support and IT landscape
A global Business Support and IT landscape enables Coloplast to scale faster and efficiently and integrate Atos Medical into the Group Global Business Services Global business services handle the majority of all global support % of group processes 100% ~90% 100% 100% IT infrastructure Finance / acco
Slide 39: EBIT margin development drivers
EBIT margin development continues to be a function of growth, scalability, cost discipline and investment activity EBIT margin (%) Illustrative Future drivers of EBIT margin EBIT will be positively impacted by: Leverage effect on fixed costs e.g. distribution, admin and R&D costs >30% especially dri
Slide 40: Continued strong development in free cash flow
Continued strong development in free cash flow during the Strive25 strategy period Taxation Net working capital CAPEX2 Reported tax rate Net working capital, % of revenue CAPEX DKKm Depreciation and amortisation, % of revenue CAPEX, % of revenue 5% 5% 5% 6% 5% 4% 5% 4% 4% 4% 4% 26% 24% 23% 24% 25% ~
Slide 41: Attractive cash returns despite investments
We will continue to provide attractive cash returns despite investments in commercial activities and the Atos Medical acquisition Coloplast cash distribution to investors Highlights Dividends paid out in the year (DKKm) (1) Share buy-back (DKKm) Pay-out ratio (%) (2) • Coloplast returns excess liqui
Slide 42: Stable shareholder returns
In sum, we believe Coloplast can continue to deliver stable shareholder returns through ... Organic growth and EBIT margin development Highlights 29% • Stable market trends in our 12% Chronic Care business 7% • Innovative product portfolio and new product 7% launches 07/08 09/10 11/12 13/14 15/16 17
Slide 43: Introduction to Atos Medical
Introduction to Atos Medical The global market leader in laryngectomy | Atos user
Slide 44: Atos Medical global pioneer within Laryngectomy
Atos Medical is the global pioneer within Laryngectomy and has shaped the market for the past +30 years Key market and business highlights Revenue by segment and geography Laryngectomy Tracheostomy Other ~50,000 New total laryngectomies per year Organic CAGR ~8% ~85% Global Laryngectomy market share
Slide 45: Atos improves lives following Total Laryngectomy
Atos improves the lives of patients following Total Laryngectomy procedures A Total Laryngectomy is a non-elective After surgery, a Voice Prosthesis (VP) is inserted by a healthcare professional, surgery performed in the advanced and the patient applies the Heat- and Moisture Exchanger (HME) and adh
Slide 46: Untapped potential in the laryngectomy market
There is significant untapped potential in the laryngectomy market today, which we will seek to eliminate The laryngectomy market, DKKbn Low level of market penetration due to: We will eliminate the ‘white space’ by: Lack of clinical standards in existing 01 markets outside of Northern Europe Settin
Slide 47: Tracheostomy patients have similar needs
Tracheostomy patients have similar needs as Laryngectomy patients, as they are both breathing through a neck stoma A Tracheostomy is a surgical The Tracheostomy patient journey starts with a cannula insertion, which can be procedure that creates an opening in reversed at any stage the neck for direc
Slide 48: Atos Medical financial assumptions
Atos Medical financial assumptions Organic growth and • Organic growth 8-10% EBITDA margin • EBITDA margin in the mid-30s level EPS impact • Increasingly EPS accretive from FY 2022/23 • Estimated run-rate operational synergies of up to DKK 100m from utilising Coloplast infrastructure with Synergies
Slide 49: Appendices
Leading intimate healthcare Leading intimate healthcare Appendices Tabitha | IC user
Slide 50: The Coloplast share
The Coloplast share (COLO-B.CO) Holders of A shares and family 1 Danish institutions Foreign institutions Coloplast A/S Coloplast share listed on Nasdaq Copenhagen Other shareholders since 1983 Non-registered shareholders 4.0% 7.0% ~182.5 billion DKK (~27 billion USD) market cap @ ~858.8 DKK per sha
Slide 51: Capital structure
Capital structure Comments Net interest-bearing debt • Overall policy is that excess liquidity is returned to shareholders through a 2.6x 2.3x combination of dividends and share buy- 2.0x backs 21,328 • Interest bearing debt will only be raised in 18,091 connection with a major acquisition, such 0.3
Slide 52: Key value ratios
Key value ratios Profitability drivers Free Cash Flow drivers 32.7 36.2 36.8 32.3 32.1 34.7 34.6 34.7 31.2 32.0 31.5 33.3 28.7 29.0 28.7 28.2 30.1 30.5 25.4 26.2 23.4 23.6 23.4 23.7 4.0 4.2 4.1 4.5 4.9 5.0 5.2 5.0 4.5 3.9 4.1 3.5 3.9 3.9 3.8 3.9 3.8 3.5 17/18 18/19 19/20 20/21 21/22 YTD 22/23 17/18
Slide 53: Revenue development by business area
Coloplast revenue development by business area Ostomy Care Interventional Urology Voice & Respiratory Care 8 6 6 10 8 19 16 18 7 7 8 13 5 4 Contribution to 8,620 14 11 7,841 reported growth 7,166 7,538 10 9 6%-points 9%-points -7 2,274 2,424 1,970 1,835 -7 2,097 NA NA NA 1,203 686 480 18/19 19/20 20
Slide 54: Revenue development by geography and total
Coloplast revenue development by geography and total Europe Other Developed Markets 6 15 16 2 4 27 5 6 2 4 5 16 21 12,916 10,573 10,820 11,261 8 6 9 11 6 3 5 4,785 5,775 3,434 4,380 4,644 1,634 18/19 19/20 20/21 21/22 YTD 22/23 18/19 19/20 20/21 21/22 YTD 22/23 FY 21/22 and YTD 22/23 reported growth
Slide 55: Segment operating profit
Segment operating profit (Excludes shared/non-allocated costs) Segment Operating Profit DKKm Segment Operating Profit Margin (%) Chronic Care Interventional Urology Wound & Skin Care Voice & Respiratory Care Ostomy and Continence Care 59 59 59 58 58 2,397 2,500 2,456 39 31 35 37 36 42 40 42 2,330 2,
Slide 56: Q1 2022/23 Atos Medical impact on EBIT
Q1 2022/23 Atos Medical impact on EBIT Atos Medical acquisition EBIT impact 33% 3% 30% 30% 29% 0% 29% 1% 0% DKK 13 DKK 54 DKK 29 DKK 178 million million million million EBIT margin Special items EBIT margin Atos EBIT Q1 Amortisation EBITA Depreciation EBITDA after special Atos Medical1 Q1 2022/23 Me
Slide 57: Exchange rate exposure and hedging policy
Exchange rate exposure FY 2022/23 and hedging policy Revenue FX exposure 2022/23(1) 12 months exposure from 10% initial exchange rate drop(1) Other 18% -490 USD -220 EUR 36% CNY, JPY, AUD, BRL & ARS -320 12% GBP -220 HUF 0 130 14% GBP 20% Revenue (DKKm) EBIT (DKKm) USD Foreign exchange rate guidance
Slide 58: US Mesh litigation financial impact
US Mesh litigation – Overview of financial impact P&L – overview of special items related to the Mesh Balance Cash flow litigation Assets Actual/Expected cash flow, DKKbn 13/14 - 18/19 19/20 20/21 21/22 YTD Restricted cash, DKKbn Actual cash flow Expected cash flow 17/18 22/23 0.5 0.5 EBIT (before s
Slide 59: Stable global health reforms environment
Stable global health reforms environment Europe Rest of World • Netherlands: Reimbursement pressure on OC and CC • U.S.: Reimbursement pressure on OC and CC (Managed Care) • France: Reimbursement pressure on WC • Italy: Regional payback system (retroactive) 59 Reimbursement pressure
Slide 60: CARE helps increase retention and compliance
CARE helps us increase retention and improve product compliance We co-develop CARE content with CARE is a personal and “high- Global program with shared local clinicians touch” program infrastructure Advisors available on phone Clinically validated content and call protocol - ERP Website with reliab
Slide 61: DtC marketing program reaches into the community
With our DtC marketing program we reach into the community We operate in numerous channels to expose our …and with the reach we get several benefits service and product offering… Expose innovative products Ensure product accessibility Ensure successful experience 61
Slide 62: Generic model for distribution and reimbursement
The generic model for distribution and reimbursement of our products Prescription & Insurance Product Reimbursement price Prescription & Insurance Payer Distribution Consumer $ Product 62
Slide 63: Interventional Urology revenue balanced geographically
Interventional Urology’s revenue is balanced geographically and across the four business areas Interventional Urology at a Glance 15-20% market share in global market of DKK 13-14bn FY 21/22 market growing 3-5% annually 11% Coloplast position, FY 21/22 of Coloplast sales Endourology Men’s Health Wom
Slide 64: Interventional Urology split into four business areas
Coloplast Interventional Urology is split into four business areas Men’s Women’s Bladder health Endourology & surgery Health Health • Erectile Dysfunction • Stress Urinary Incontinence • Stone Management • Bladder Drainage • Male Incontinence (SUI) • Transurethral • Benign prostatic hyperplasia • Te
Slide 65: Strong presence in Interventional Urology categories
We have a strong presence in our categories in Interventional Urology but there is room to capture market share 1 Men’s Health Women’s Health Endourology Bladder Health & 1 Surgery Inflatable Penile Male Stress urinary Pelvic organ Prosthesis (IPP) incontinence incontinence prolapse Fragmented Compe
Slide 66: Refined product roadmap in Interventional Urology
We are executing a refined product roadmap in Interventional Urology aligned to Strive25; progress is tracking to key milestones Strategy Description Men’s Health Women’s Health Endourology Projects that address regulatory Cadence of stone Strengthen core requirements, close gaps and maintain IPP En
Slide 67: Growth through product and therapy expansion
We will deliver growth through product and therapy expansion Tissue Fixation System Implantable Tibial Nerve TECHNOLOGY ASSESSMENT Stimulator Launched 22/23 Launching 25/26 ACTIVELY PURSUING POP SUI AUS Cancer ED IU Today OAB Endo Endo Consum- ables Laser Endo Visualization Soprano® BPH Hybrid Guide
Slide 68: Nine Continents acquisition to enter OAB market with Intibia
With the acquisition of Nine Continents, we are executing on the option to enter the attractive OAB market with Intibia Overactive bladder (OAB) market Why Implantable Tibial Nerve Stimulation (ITNS)? Less invasive ITNS complete in single procedure +80m people globally suffer from OAB symptoms proce
Slide 69: Global Advanced Wound Care market large and growing
The global Advanced Wound Care market remains large and growing The Advanced Wound Care market remains a significant Silicone Foams and Gelling Fibers are the two biggest value pool and is expected to grow despite the pandemic categories and grow faster than the market Market size in DKKbn Market si
Slide 70: Wound & Skin Care 2025 strategic plan
The Wound & Skin Care 2025 strategic plan Scale our China business Build on positive momentum in EU by strengthening our commercial in silicone and 3DFit Technology and foundation and accelerate in silicone increase share of voice in selected with 3DFit Technology markets Scale our US business in Ac
Slide 71: In US Ostomy Care we continue to win
In US Ostomy Care we continue to win across patient pathway We have gained significant share over the last years … as we work on multiple fronts to win across the patient pathway 3-5 days >60 days ~10 years Bags & Plates acute share Acute Post-acute Community +10%-pts Patients’ first (incl. HHA) Lon
Slide 72: Access to Vizient and Premier GPOs
Coloplast has been awarded access to Vizient and Premier GPOs, ensuring a level playing field in ~75% of acute accounts Coloplast has been awarded access to Vizient and Premier, the two largest GPOs in the US Acute Estimated Contract start Contract Contract members1 Acute share2 date length type Pre
Slide 73: Sustainability key priorities and actions
Sustainability - key priorities and actions Improving products Reducing emissions Responsible and packaging operations Why is this a key priority: Why is this a key priority: Why is this a key priority: As a manufacturer of medical products made primarily As a growing company, we are challenged by a
Slide 74: Q1 progress on key sustainability ambitions
Q1 22/23 progress on key sustainability ambitions – carbon emission targets approved by the SBTi* in June 2022 Improving products and packaging Reducing emissions2 Responsible operations 2025 Q1 FY 2025 Q1 FY 2025 Q1 FY Ambition 22/23 21/22 Ambition 22/23 21/22 Ambition 22/23 21/22 100% 2.4 2.4 90%
Slide 75: Introducing Ostomy Care
Introducing Key products Ostomy Care Disease areas • Colorectal cancer (est. 45%) • Bladder cancer (est. 10%) SenSura® Mio Concave SenSura® Mio Convex SenSura® Mio • Diverticulitis (est. 15%) Launched in 2018-2019 Launched in 2015 Launched in 2014 • Inflammatory bowel disease (est. 10%) • Other (est
Slide 76: Ostomy Care Supporting Products
Introducing Key products Ostomy Care Supporting Products Market fundamentals Brava® Protective Seal Brava® Skin Barrier Brava® Elastic Tape Designed for leakage and skin Reducing skin problems Elastic so it follows • Market size of DKK 3-4bn protection without affecting adhesion the body and • Marke
Slide 77: Introducing Continence Care
Introducing Key products Continence Care Disease areas • Spinal Cord Injured, SCI Luja™ SpeediCath® Flex Set SpeediCath® Navi SpeediCath® Flex • Spina Bifida, SB Intermittent catheter with Intermittent Set catheter Intermittent catheter Intermittent catheter • Multiple Sclerosis, MS Micro-hole Zone
Slide 78: Bowel Management
Introducing Key products Bowel Management Disease areas Faecal incontinence (management products only) Peristeen® Plus Anal Irrigation Peristeen® Anal Irrigation Anal plug Launched in 2021 Launched in 2003 Launched in 1995 Customer groups Updated in 2011 • Spinal Cord Injured, SCI • Spina Bifida, SB
Slide 79: Laryngectomy
Introducing Key products - Laryngectomy Voice & Respiratory Care Provox® Life ™ Laryngectomy Heat and Moisture Exchangers (HMEs) Home Go Night Protect Energy Free hands Disease areas • People that have undergone a total Provox® Life ™ laryngectomy, a typical treatment for Adhesive advanced laryngeal
Slide 80: Tracheostomy
Introducing Voice & Respiratory Care Tracheostomy Disease areas Key products - Tracheostomy • Performed when the airways are restricted, e.g., during an emergency when the airways are Portfolio expansion blocked, or when a disease or other problem • Strengthened the tracheostomy makes normal breathi
Slide 81: Surgical treatment of urological disorders
Introducing Key products Interventional Urology Surgical treatment of urological disorders Disease areas Titan® Touch Inflatable Penile Prosthesis Altis® single incision sling • Urinary incontinence Launched in 2013, Men’s health Launched in 2012 Women’s health – Surgical Urology • Pelvic organ prol
Slide 82: Wound Care
Key products Introducing Wound Care Disease areas Chronic wounds Biatain® Silicone Non-Border Biatain® Fiber Biatain® Contact • Leg ulcers Silicone foam dressing without a Reinforced gelling fiber. Silicone contact layer. • Diabetic foot ulcers border. Launched in 2021 Launched in 2020 Launched in 2
Slide 83: Skin Care
Introducing Key products Skin Care Disease areas • Moisture associated skin damage Sween® EasiCleanse® Bath • Incontinence Broad line of skin care products Disposable bathing wipes • Skin folds & obesity Designed to increase consistency of care Improves patient experience • Prevention of skin impair
Slide 84: US Skin Care at a glance
At a glance US Skin Care US Skin Care market Market Market drivers drivers andand limiters limiters + +AgingAging and obese population and obese population US market size estimated + +CMSCMSValueValue BasedBased Purchasing Purchasing at DKK 4-5bn with 2-4% growth + +Increased focusfocus Increased on
Slide 85: Coloplast organisation structure
The Coloplast organisation is divided into Chronic Care and Strategic Business Units, running on shared global business support functions Coloplast Group Chronic Care Strategic Business Unit Wound Interventional Voice & Ostomy Care Continence Care & Skin Care Urology Respiratory Care Marketing Marke
Slide 86: The Coloplast Executive Leadership Team
The Coloplast Executive Leadership Team Kristian Villumsen President, CEO (Born 1970) With Coloplast since 2008 Nicolai Buhl Andersen Anders Lonning-Skovgaard Paul Marcun Dorthe Rønnau Allan Rasmussen EVP, Innovation EVP, CFO EVP, Growth SVP, People & Culture EVP, Operations (Born 1969) (Born 1972)
Slide 87: Income statement
Income statement DKKm Q1 2021/22 Q1 2022/23 Change Revenue 5,169 6,105 18% Gross profit 3,530 4,146 17% SG&A costs -1,687 -2,162 28% R&D costs -205 -216 5% Other operating income/expenses 11 6 -45% Operating profit (EBIT) before special items 1,649 1,774 8% Special items -34 -13 -62% Operating profi
Slide 88: Balance sheet
Balance sheet DKKm 31 Dec 2021 31 Dec 2022 Change Balance, total 16,188 35,221 118% Assets Non-current assets 8,904 25,942 191% Current assets 7,284 9,279 27% of which: Inventories 2,497 3,397 36% Trade receivables 3,215 3,953 23% Marketable securities, cash, and cash equivalents 864 881 2% 675 Equi
Slide 89: Cash flow
Cash flow DKKm Q1 2021/22 Q1 2022/23 Change EBIT 1,615 1,761 9% Amortisation 21 83 295% Depreciation 154 178 16% Adjustment for other non-cash operating items -19 -73 284% Change in working capital 63 -501 nm Net interest payments -92 -81 -12% Paid tax -611 -880 44% Cash flow from operations 1,131 4
Slide 90: Manufacturing setup
Manufacturing setup Production by country (Volume)¹ 3% 5% Hörby Hungary Mørdrup 0% Tatabánya China 11% Minneapolis Nieder-Olm 4% Nyirbátor Mankato Sarlat US/France Denmark Zhuhai Costa Rica Costa Rica Atos (SE/DE) 77% COGS by cost type² 11% 9% Salary - Direct 6% 12% Salary - Indirect Materials (RM &
Slide 91: Production sites
Production sites Hungary China Tatabánya Zhuhai • Ostomy care products • Continence care products • Adhesives • Ostomy care products • Continence care products • Machine building • Interventional Urology products • Number of employees in production: ~900 • Number of employees in production: ~1,800 T
Slide 92: Production sites
Production sites Denmark Germany Mørdrup Nieder-Olm • Pilot development work Ostomy care, • Specialised production Continence care and Wound care • Research & Development centre and • Adhesives production manufacturing of tracheostomy products • Number of employees in production: ~200 • Number of em
Slide 93: Global Operations Plan 6 to be announced in 2023
Our Global Operations Plan 6 will be announced in 2023, key themes will be resilience and optimizing the footprint Moving focus of GOP6 to further strengthening our model while delivering continued leverage effect on fixed costs and efficiency improvement 2008 2009 2012 2017 2020 2023-2026 Turn-arou
Slide 94: Coloplast Sponsored Level 1 ADR programme
Coloplast Sponsored Level 1 ADR programme Coloplast Sponsored ADR Programme Benefits of a Coloplast ADR programme to US Investors: • Coloplast has established a sponsored ADR programme in the US, as a Symbol CLPBY service to US investors by offering an alternative way to trade Coloplast shares, whil
Slide 95: Contact Investor Relations
Contact Investor Relations Holtedam 1 DK-3050 Humlebæk Denmark Aleksandra Dimovska Kristine Husted Munk Otto Munk Madsen Director, Investor Relations Senior Manager, Investor Relations Junior Assistant, Investor Relations Tel. direct: +45 4911 2458 Tel. direct: +45 4911 3266 Tel. direct: +45 4911 32
Slide 96: Mission, values and vision
Mission Making life easier for people with intimate healthcare needs Values Closeness… to better understand Passion… to make a difference Respect and responsibility… to guide us Vision Setting the global standard for listening and responding